KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Neogenomics (NEO) EBITDA: 2009-2025

Historic EBITDA for Neogenomics (NEO) over the last 17 years, with Sep 2025 value amounting to -$27.0 million.

  • Neogenomics' EBITDA fell 27.44% to -$27.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$120.9 million, marking a year-over-year decrease of 30.98%. This contributed to the annual value of -$92.1 million for FY2024, which is 14.51% up from last year.
  • As of Q3 2025, Neogenomics' EBITDA stood at -$27.0 million, which was up 43.28% from -$47.6 million recorded in Q2 2025.
  • Neogenomics' 5-year EBITDA high stood at -$15.1 million for Q1 2021, and its period low was -$52.0 million during Q1 2022.
  • Moreover, its 3-year median value for EBITDA was -$27.0 million (2025), whereas its average is -$27.5 million.
  • Its EBITDA has fluctuated over the past 5 years, first tumbled by 950.57% in 2021, then surged by 38.76% in 2023.
  • Over the past 5 years, Neogenomics' EBITDA (Quarterly) stood at -$41.6 million in 2021, then skyrocketed by 36.53% to -$26.4 million in 2022, then grew by 29.60% to -$18.6 million in 2023, then increased by 0.93% to -$18.4 million in 2024, then fell by 27.44% to -$27.0 million in 2025.
  • Its EBITDA was -$27.0 million in Q3 2025, compared to -$47.6 million in Q2 2025 and -$27.8 million in Q1 2025.